Heart failure (HF) in cardio-oncology patients during anticancer therapy is usually regarded as an accelerated form of classical HF, which restricts early diagnosis and timely pathogenetically based treatment. Myocardial decompensation in these patients appears to involve distinct molecular mechanisms detectable...
R. Alieva, K. Fozilov, M. Yakhyoeva et al.· European Heart Journal, Supp...· 0 citations
Endothelin-1 is a promising early diagnostic and prognostic biomarker of subclinical anthracycline-induced vascular toxicity in lymphoma patients with low and intermediate CVT-risk receiving anthracycline-based chemotherapy and may facilitate early risk reclassification and optimization of cardio-oncology surveillance...
R. Alieva, K. Fozilov, M. Yakhyoeva et al.· European Heart Journal, Supp...· 0 citations
In patients with low and moderate baseline CV risk, a statistically significant deterioration in lipid profile was observed during chemotherapy, which is consistent with the development of subclinical endothelial dysfunction and early vascular toxicity, despite the absence of overt clinical manifestations of vasculotox...
R. Alieva, K. Fozilov, M. Yakhyoeva et al.· European Heart Journal, Supp...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.